Novartis announced that Hervé Hoppenot, president of Novartis Oncology, will leave the company with immediate effect having decided to pursue a career opportunity outside of the organization.
Alessandro Riva, MD, global head, Novartis Oncology Development and Medical Affairs, will take on the role of president of Novartis Oncology ad interim, in addition to his current role, until a successor is named in due course.
Hervé has led the oncology business since 2010 and we thank him for his dedication and commitment to bringing breakthrough treatments to patients. We wish him all the best for his future success.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. The company offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products.